Application No. 10/539,893 - - - - 7

Remarks

Claims 1-36 are under consideration. The indication that claims 9-12 define allowable subject matter is noted with appreciation.

Claim 37 is canceled without prejudice in order to overcome the double patenting rejection under 35 U.S.C. 101.

A Terminal Disclaimer is submitted herewith in order to overcome the non-statutory, obviousness-type double patenting rejection. Accordingly, claims 1-8 and 13-36 should be allowable as well.

Inasmuch as the Terminal Disclaimer obviates the rejection of claim 1 and renders claim 1 allowable, there appears to be no need to rewrite claims 9-12 in independent form.

The present amendment to the claims canceling claim 37 and the accompanying Terminal Disclaimer are deemed to place this application in condition for allowance. Early passing of this case to issue is solicited.

Kindly charge the Terminal Disclaimer fee (\$65.00) contemplated by 37 C.F.R. 1.20(d) to our Deposit Account No. 15-0508.

Change in Entity Status

Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

Respectfully submitted.

October 29, 2007

Falivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD. 20 North Wacker Drive 36th Floor Chicago, Illinois 60606 (312) 580-1180